TradingKey

關於 ANI Pharmaceuticals Inc 公司

ANI Pharmaceuticals, Inc. 是一家多元化生物製藥公司，通過開發、製造和營銷品牌和仿製處方藥產品（包括針對未滿足醫療需求的疾病）爲有需要的患者提供服務。該公司專注於通過其主要資產 Purified Cortrophin Gel 擴大其罕見病業務以及通過增強研發能力的仿製藥業務，實現可持續增長。該公司擁有三家制藥廠，其中兩家位於明尼蘇達州的 Baudette，一家位於新澤西州的 East Windsor，這些工廠共同能夠生產口服固體劑量產品以及半固體、液體和外用藥、管制物質和強效產品。該公司擁有約 118 種產品的商業組合，具有多種適應症和強大的產品線組合。

公司簡介

公司代碼ANIP

公司名稱ANI Pharmaceuticals Inc

上市日期May 04, 2000

CEOMr. Nikhil Suresh Lalwani

員工數量897

證券類型Ordinary Share

年結日May 04

公司地址210 Main Street West

城市BAUDETTE

上市交易所NASDAQ Global Market Consolidated

國家United States of America

郵編56623

電話12186343500

網址https://www.anipharmaceuticals.com/

公司代碼ANIP

上市日期May 04, 2000

CEOMr. Nikhil Suresh Lalwani

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

468.18K

+5.44%

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

310.13K

+8.36%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

92.59K

+12.47%

Mr. Ori Gutwerg

Senior Vice President - Generics

89.90K

-0.97%

Mr. Patrick D. Walsh

Independent Chairman of the Board

79.05K

+5.80%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

64.66K

-4.24%

Mr. Thomas J. (Tom) Haughey, J.D.

Independent Director

55.86K

+8.42%

Mr. Thomas Andrew (Thom) Rowland

Senior Vice President, Head of Established Brands

45.02K

+35.72%

Dr. Renee P. Tannenbaum, Pharm.D.

Independent Director

26.96K

+19.17%

Mr. Matthew J. (Matt) Leonard

Independent Director

16.33K

+36.15%

名稱

名稱/職務

職務

持股

持股變動

Mr. Nikhil Suresh Lalwani

President, Chief Executive Officer, Director

468.18K

+5.44%

Mr. Chad Gassert

Senior Vice President - Corporate Development and Strategy

310.13K

+8.36%

Mr. Muthusamy Shanmugam

Director, Head of Research and Development, Chief Operating Officer - Novitium Operations

92.59K

+12.47%

Mr. Ori Gutwerg

Senior Vice President - Generics

89.90K

-0.97%

Mr. Patrick D. Walsh

Independent Chairman of the Board

79.05K

+5.80%

Ms. Krista Davis

Chief Human Resources Officer, Senior Vice President

64.66K

-4.24%

收入明細

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

業務USD

名稱

營收

佔比

Sales of generic pharmaceutical products

98.68M

0.00%

Sales of rare disease pharmaceutical products

52.85M

0.00%

Sales of Cortrophin Gel

52.85M

0.00%

Sales of branded pharmaceutical products

29.48M

0.00%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

Sales of generic pharmaceutical products

98.68M

0.00%

Sales of rare disease pharmaceutical products

52.85M

0.00%

Sales of Cortrophin Gel

52.85M

0.00%

Sales of branded pharmaceutical products

29.48M

0.00%

股東統計

更新時間: 5月16日週五

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

11.27%

The Vanguard Group, Inc.

5.44%

Meridian Venture Partners

5.38%

Millennium Management LLC

5.16%

Global Alpha Capital Management Ltd.

3.40%

Other

69.35%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

11.27%

The Vanguard Group, Inc.

5.44%

Meridian Venture Partners

5.38%

Millennium Management LLC

5.16%

Global Alpha Capital Management Ltd.

3.40%

Other

69.35%

股東類型

持股股東

佔比

Investment Advisor

41.99%

Investment Advisor/Hedge Fund

21.79%

Hedge Fund

20.04%

Research Firm

8.69%

Individual Investor

8.42%

Private Equity

5.38%

Corporation

2.94%

Bank and Trust

1.38%

Pension Fund

0.90%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

504

24.16M

111.60%

-1.18M

2025Q1

511

24.19M

111.77%

-1.42M

2024Q4

489

23.75M

109.53%

-1.38M

2024Q3

473

23.30M

110.79%

+2.44M

2024Q2

446

19.77M

94.29%

-402.06K

2024Q1

424

18.72M

89.20%

-877.00K

2023Q4

409

18.10M

88.69%

-881.29K

2023Q3

396

18.38M

91.57%

-127.77K

2023Q2

370

17.73M

90.91%

+852.82K

2023Q1

341

15.70M

87.63%

-1.26M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

2.44M

11.27%

-89.22K

-3.53%

Mar 31, 2025

The Vanguard Group, Inc.

1.18M

5.44%

-132.90K

-10.14%

Mar 31, 2025

Meridian Venture Partners

1.16M

5.38%

-255.00K

-17.97%

Mar 11, 2025

Millennium Management LLC

1.12M

5.16%

+298.32K

+36.45%

May 30, 2025

Global Alpha Capital Management Ltd.

735.59K

3.4%

+111.04K

+17.78%

Mar 31, 2025

Citadel Advisors LLC

723.33K

3.34%

+131.74K

+22.27%

Mar 31, 2025

State Street Global Advisors (US)

714.57K

3.3%

-22.72K

-3.08%

Mar 31, 2025

Deep Track Capital LP

700.00K

3.23%

+50.96K

+7.85%

Mar 31, 2025

Esjay L.L.C,

632.62K

2.92%

-200.00K

-24.02%

Mar 14, 2025

Dimensional Fund Advisors, L.P.

631.56K

2.92%

-54.17K

-7.90%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

Invesco Pharmaceuticals ETF

3.03%

SPDR S&P Pharmaceuticals ETF

2.41%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.71%

Invesco S&P SmallCap Health Care ETF

0.79%

iShares U.S. Pharmaceuticals ETF

0.56%

First Trust Small Cap Growth AlphaDEX Fund

0.54%

Invesco S&P SmallCap 600 Pure Growth ETF

0.46%

VictoryShares US Small Mid Cap Value Momentum ETF

0.38%

First Trust Small Cap Core Alphadex Fund

0.29%

First Trust Active Factor Small Cap ETF

0.24%

Invesco Pharmaceuticals ETF

佔比3.03%

SPDR S&P Pharmaceuticals ETF

佔比2.41%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.71%

Invesco S&P SmallCap Health Care ETF

佔比0.79%

iShares U.S. Pharmaceuticals ETF

佔比0.56%

First Trust Small Cap Growth AlphaDEX Fund

佔比0.54%

Invesco S&P SmallCap 600 Pure Growth ETF

佔比0.46%

VictoryShares US Small Mid Cap Value Momentum ETF

佔比0.38%

First Trust Small Cap Core Alphadex Fund

佔比0.29%

First Trust Active Factor Small Cap ETF

佔比0.24%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

ANI Pharmaceuticals Inc

64.160USD

ANI Pharmaceuticals Inc

64.160

概覽

公司

財務